Table 5.
Performance of predRCB for Predicting Responses to NACT in the Different Subgroups
| Subtype | Favourable Response | Resistant Response | ||||||
|---|---|---|---|---|---|---|---|---|
| AUC | SE | 95% CI | P value | AUC | SE | 95% CI | P value | |
| Molecular subtype | ||||||||
| Luminal A | 1.00 | 0.000 | 1.00–1.00 | 0.005 | 0.93 | 0.07 | 0.79–1.00 | 0.01 |
| Luminal B | 0.90 | 0.044 | 0.81–0.98 | <0.001 | 0.91 | 0.04 | 0.83–0.99 | <0.001 |
| Triple negative | 0.89 | 0.101 | 0.69–1.00 | 0.010 | – | – | – | – |
| HER2 | 0.95 | 0.05 | 0.85–1.00 | 0.003 | 0.78 | 0.17 | 0.44–1.00 | 0.20 |
| Pathological types | ||||||||
| Invasive ductal carcinoma | 0.86 | 0.04 | 0.78–0.94 | <0.001 | 0.92 | 0.03 | 0.86–0.97 | <0.001 |
| Invasive lobular carcinoma | 1.00 | 0.00 | 1.00–1.00 | 0.014 | 0.95 | 0.07 | 0.81–1.00 | 0.03 |
| Grade | ||||||||
| Grade 2 | 0.88 | 0.04 | 0.81–0.95 | <0.001 | 0.90 | 0.03 | 0.84–0.97 | <0.001 |
| Grade 3 | 1.00 | 0.00 | 1.00–1.00 | 0.005 | 1.00 | 0.00 | 1.00–1.00 | 0.003 |
| Tumor size (cT) | ||||||||
| T1 | 0.57 | 0.20 | 0.19–0.96 | 0.770 | – | – | – | – |
| T2 | 0.84 | 0.05 | 0.75–0.94 | <0.001 | 0.88 | 0.04 | 0.80–0.96 | <0.001 |
| T3 | 1.00 | 0.00 | 1.00–1.00 | <0.001 | 0.96 | 0.03 | 0.90–1.00 | <0.001 |
| NACT regimens: | ||||||||
| TEC | 0.93 | 0.03 | 0.86–1.00 | <0.001 | 0.92 | 0.03 | 0.85–0.98 | <0.001 |
| TE | 0.64 | 0.18 | 0.30–0.99 | 0.450 | 1.00 | 0.00 | 1.00–1.00 | 0.114 |
| FEC | – | – | – | – | 0.79 | 0.15 | 0.48–1.00 | 0.242 |
| TH | 0.75 | 0.11 | 0.54–0.96 | 0.261 | 1.00 | 0.00 | 1.00–1.00 | 0.008 |
Note: “–“: Unable to calculate due to small sample size after subgrouping.
Abbreviations: NACT, neoadjuvant chemotherapy; TEC, (docetaxel, epirubicin, and cyclophosphamide); TE (docetaxel and epirubicin); FEC (5-fluorouracil, epirubicin, and cyclophosphamide); TH (docetaxel and herceptin); AUC, area under the receiver operating characteristic curve; SE, standard error. CI, confidence interval.